APVO ▼ -1.5% - Aptevo Therapeutics Inc.
$APVO Aptevo Achieves Key Clinical Development Objective, Significantly Reducing Infusion-Related Reactions with Mipletamig in Frontline AML
05-NOV-2026 08:33 AM ET
Share this post
More filings for $APVO
APVO ▲ +7.3% - Aptevo Therapeutics Inc.Nov 5, 2026APVO ▼ -0.6% - Aptevo Therapeutics Inc.Oct 26, 2026APVO ▼ -1.2% - Aptevo Therapeutics Inc.Oct 14, 2026APVO ▲ +4.5% - Aptevo Therapeutics Inc.Oct 12, 2026APVO ▲ +2.1% - Aptevo Therapeutics Inc.Sep 24, 2026APVO ▼ -12.7% - Aptevo Therapeutics Inc.Sep 3, 2026
View full $APVO filing history →💬 Comments
Loading comments…
Leave a comment